We thank Drs Yip and Deng1 for their insights on our case report.2 We agree that frequent clinical and laboratory assessment in a patient with life-threatening hemorrhage is essential. Clinical examination of this critically ill patient was constant, and coagulation parameters were measured 10 times during his 3-day hospital course (approximately every 4 hours). We also agree that repeat dosing of idarucizumab may have been beneficial had it been possible, as in the report we cited of dabigatran toxicity in acute kidney injury (AKI).